About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
Multi-media
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
EN
简体
EN
繁體
Home
About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Event
Popular Science
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
Be the most trusted biotech company
Press Release
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Popular Science
Highlights
Download
Media Reports
Media Enquiry
2019-10-31
Henlius Anti-HER2 Monoclonal Antibody HLX11 Received IND Application Acceptance Notification from NMPA
2019-10-17
Henlius Innovative Anti-cMET Monoclonal Antibody HLX55 Received Clinical Approval from NMPA
2019-10-12
The breakthrough of China-manufactured trastuzumab biosimilar (HLX02) for metastatic breast cancer︱Interview of Prof. Binghe Xu and Prof. Igor Bondarenko at ESMO Congress 2019
2019-10-09
Top Dialogue | Prof. Yuankai Shi &. Prof. J. Fitzgibbon: Efficacy and the outlook of HLX01(Hanlikang®)in non-Hodgkin’s lymphoma.
2019-09-30
Henlius and KG Bio Enter into Exclusive License Agreement for Henlius Novel Anti-PD-1 mAb HLX10
2019-09-12
Henlius and KG Bio Announce a Collaboration for Henlius Novel Anti-PD-1 mAb HLX10 in the Asia Pacific Region
2019-09-07
The Confirmatory Phase 3 Study Results of First China-Manufactured Trastuzumab Biosimilar, HLX02, will be Presented at Both CSCO and ESMO This Year
2019-08-30
2019 ESMO Henlius Abstract Release
2019-08-20
Monoclonal Antibody HLX10 in Patients with Metastatic MSI-H/dMMR Solid Tumors
1
...
31
32
33
34
35
36
...
38